EDAP TMS SA (EDAP: Quote) issued an update regarding its Ablatherm-HIFU (High Intensity Focused Ultrasound) ENLIGHT U.S. clinical trial for the indication of low risk, localized prostate cancer.
According to the company, the trial is a multi-center U.S. Phase II/III clinical trial conducted under an Investigational Device Exemption granted by the FDA. The last Ablatherm-HIFU patient was treated in June 2010. The two year anniversary of the last patient treated occurred on June 30, 2012, which marked the conclusion of the two year follow-up phase, and EDAP confirmed the completion of all two year follow-up visits.
John Rewcastle, medical director of EDAP-TMS, commented, "After the second anniversary of the last patient treated, and according to the approved protocol, patients have two months to present at the trial sites for their last follow-up visit. Now that every patient has completed their follow-up visit, we will be in a position to commence the clinical analysis of the collected data. In parallel with this analysis, EDAP's team in the U.S. and France has already started to compile the comprehensive Premarket Approval (PMA) submission that includes a detailed review of the Company's technical and manufacturing capabilities, along with the clinical analysis of the collected U.S. patient data."
 | | To receive FREE breaking news email alerts for EDAP TMS SA ADR and others in your portfolio |
|
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News